Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,001 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety and Efficacy Assessments Clear all
Active, not recruiting Phase 3 Interventional

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

NCT06079372
View directory record Official record
Conditions
Hypophosphatasia
Interventions
ALXN1850, asfotase alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Hartford, Connecticut • Baltimore, Maryland • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

XTX301 in Patients With Advanced Solid Tumors

NCT05684965
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
XTX301
Drug
Lead sponsor
Xilio Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Sacramento, California • New Haven, Connecticut • Saint Louis Park, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 3 Interventional

Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes

NCT01421966
View directory record Official record
Conditions
Lower Extremity Chronic Ulcers in Diabetics
Interventions
CureXcell®, Sham injection
Biological
Lead sponsor
Macrocure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
31
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy

NCT02762929
View directory record Official record
Conditions
Postoperative Pain, Bunions
Interventions
HTX-011A, Saline Placebo, HTX-011B, HTX-002, Bupivacaine HCl, HTX-009
Drug · Biological
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Anaheim, California • Bakersfield, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Not applicable Interventional

Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne

NCT01162837
View directory record Official record
Conditions
Acne
Interventions
BEAM device
Device
Lead sponsor
Oregon Aesthetic Technologies
Industry
Eligibility
15 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Miami Beach, Florida • Warren, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

NCT00079937
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo, Fluticasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia

NCT05620901
View directory record Official record
Conditions
Vitreoretinopathy, Coats' Disease, Exudative Retinopathy, Lattice Degeneration, Retinal Hole, Sickler's Syndrome, Retinal Detachment Rhegmatogenous, Retinal Detachment Exudative, Retinal Detachment Traction
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Pred Forte
Drug
Lead sponsor
Lejla Vajzovic, MD, FASRS
Other
Eligibility
3 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males

NCT03318731
View directory record Official record
Conditions
Muscle Damage, Inflammation
Interventions
Sugar Pill, Fenugreek Extract, Low Dose, Fenugreek Extract, High Dose
Other · Dietary Supplement
Lead sponsor
University of Mary Hardin-Baylor
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Belton, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 9, 2026, 4:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of RSB11-HI Postbiotic Supplementation for Supporting Weight Management, Metabolic Wellness, and Quality of Life in Healthy Adults

NCT07788833
View directory record Official record
Conditions
Healthy Adults
Interventions
RSB11-HI Heat-Inactivated Postbiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Able Biolabs, LLC
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)

NCT00734747
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Medigus SRS endoscopic stapling system
Device
Lead sponsor
Aviel Roy-Shapira, M.D.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
San Diego, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

NCT04376684
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome
Interventions
Otilimab, Placebo 1, Placebo 2, Standard of care
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Mobile, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 9, 2026, 4:02 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

NCT06696443
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
65
States / cities
Anniston, Alabama • Daphne, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

NCT02728752
View directory record Official record
Conditions
Dermatomyositis
Interventions
Octagam 10%, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years to 79 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Huntington Beach, California • Los Angeles, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 9, 2026, 4:02 AM EDT
Withdrawn Not applicable Interventional

Evaluation of the XACT Robotic System for Image-guided Percutaneous Lung Procedures

NCT04612985
View directory record Official record
Conditions
CT-guided Minimally Invasive Procedures e.g. Biopsies
Interventions
XACT Robotic System
Device
Lead sponsor
Xact Robotics Ltd.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

NCT03387852
View directory record Official record
Conditions
Asthma
Interventions
SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

NCT00918255
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
adalimumab, Placebo
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Bakerfield, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy Surgery

NCT02284243
View directory record Official record
Conditions
Pain, Post-operative
Interventions
Intranasal Dexmedetomidine, Intranasal Placebo
Drug
Lead sponsor
Baudax Bio
Industry
Eligibility
18 Years to 70 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Bakersfield, California • Pasadena, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 9, 2026, 4:02 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT04408755
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Fort Smith, Arkansas • La Jolla, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 9, 2026, 4:02 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Efficacy and Safety of Votiva for Vaginal Rejuvenation

NCT03520426
View directory record Official record
Conditions
Vaginal Atrophy, Vaginal Relaxation, Stress Urinary Incontinence
Interventions
Votiva RF
Device
Lead sponsor
Walden, Jennifer L., M.D.,P.L.L.C.
Individual
Eligibility
25 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
New York, New York • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Not applicable Interventional

Electrodermabrasion Compared to Dermabrasion

NCT01769989
View directory record Official record
Conditions
Scar
Interventions
Electrodermabrasion, Dermabrasion
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of Cognitive Behavior Therapy for People With Post-traumatic Stress and Cardiovascular Illness

NCT00364910
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Cognitive behavioral therapy (CBT), Educational session and treatment as usual
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
New York, New York • Queens, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD

NCT02887859
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Human Acellular Vessel (HAV)
Biological
Lead sponsor
Humacyte, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
5
States / cities
San Francisco, California • Boston, Massachusetts • Flint, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT04014790
View directory record Official record
Conditions
Graft Vs Host Disease, Graft-versus-host-disease, Acute-graft-versus-host Disease, Prevention of aGVHD
Interventions
RGI-2001, Standard of Care
Drug
Lead sponsor
Regimmune Corporation
Industry
Eligibility
18 Years to 64 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults

NCT01046682
View directory record Official record
Conditions
HIV, Endothelial Dysfunction, Inflammation, Insulin Resistance
Interventions
Salsalate
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Oct 9, 2026, 4:02 AM EDT